Arzneimittelforschung 2008; 58(7): 328-335
DOI: 10.1055/s-0031-1296515
Antiemetics · Gastrointestinal Drugs · Urologic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Intravesical Glycosaminoglycan Replenishment with Chondroitin Sulphate in Chronic Forms of Cystitis

A multi-national, multi-centre, prospective observational clinical trial
Jørgen Nordling
1   Copenhagen University Hospital, Herlev, Denmark
Arndt van Ophoven
2   Münster University Hospital, Münster, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)


Effectiveness, safety, and tolerability of instillation therapy with chondroitin sulphate (CAS 9082-07-9, Gepan® instill) was investigated in a non-interventional study. 286 patients with clinically diagnosed chronic forms of cystitis, such as bladder pain syndrome/interstitial cystitis, radiation cystitis, overactive bladder syndrome and chronically-recurring cystitis were included. The course of symptoms was documented over 8 instillations at maximum, covering a period of approximately three months. All main symptoms of chronic cystitis declined consistently and statistically significantly (p < 0.0001). Both daytime and nighttime micturition frequencies as well as the score levels of urgency and pain declined significantly during the course of treatment. The functional bladder capacity as indicated by the volume of first morning voiding increased from 157.9 ml ± 7.5 to 186.7 ml ± 6.9 (mean ± SE; p < 0.0001). The level of urgency decreased from 6.8 ± 0.1 to 3.4 ± 0.2 (mean ± SE; numerical rating scale (11-point box scale); p < 0.0001) and nocturia decreased from 4.0 ± 0.2 to 2.1 ± 0.1 times (mean ± SE; p < 0.0001).

Chondroitin sulphate instillation was effective and well tolerated in the therapy of chronic forms of cystitis associated with a possible GAG layer deficit (GAG layer: mainly composed of the glycosaminoglycans chondroitin sulphate, dermatan sulphate and heparan sulphate), but the results need to be confirmed in a controlled study.

  • References

  • 1 Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol. 1990; 143: 139-142
  • 2 Kurth KH, ed. Interstitial Cystitis, 1st ed. Hamburg: Ergebnisse Verlag; 2003.
  • 3 Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998; 159: 1862-1866
  • 4 Hurst RE. A deficit of proteoglycans on the bladder uroep-ithelium in interstitial cystitis. Eur Urol Suppl. 2003; 2: 10-13
  • 5 Ueda T, Sant GR, Hanno PM, Yoshimura N. Interstitial cystitis and frequency-urgency-syndrome (OAB syndrome). Int J Urol. 2003; 10: S39-S48
  • 6 Hohlbrugger G. Urinary potassium and the overactive bladder. BJU Int. 1999; 83 Suppl (2) 22-28
  • 7 Parsons CL, Stein PC, Bidair M, Lebow D. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn. 1994; 13: 515-520
  • 8 Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004; 93: 1262-1266
  • 9 Van de Meswe JP, Nordling J, Bouchelouche P, Bouche-louche K, Cervigni M, Daha LK et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/ Interstitial cystitis: an ESSIC proposal. Eur Urol. 2008; 53: 60-67
  • 10 Nordling J, Anjum FH, Bade JJ, Bouchelouche P, Cervigni M, Elneil S et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol. 2004; 45: 662-669
  • 11 Van Ophoven A, Hertle L. Long-term results of amitrip-tyline treatment for interstitial cystitis. J Urol. 2005; 174: 1837-1840
  • 12 Van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J Urol. 2007; 177: 552-555
  • 13 Kurth KH, Parsons CL. The interstitial cystitis syndrome: intravesical and oral treatment. Eur Urol Suppl. 2003; 2: 2-9
  • 14 Van Ophoven A, Oberpenning F. [Interstitial cystitis: An important differential diagnosis]. Urologe A. 2006; 45: 451-452 455–456
  • 15 Bouchelouche K, Nordling J, Hald T. Bouchelouche E The cysteinyl leukotriene D4 receptor antagonist Montelukast for the treatment of interstitial cystitis. J Urol. 2001; 166: 1734-1737
  • 16 Michael YL, Kawachi I, Stampfer MJ, Colditz GA, Curhan GC. Quality of life among women with interstitial cystitis. J Urol. 2000; 164: 423-427
  • 17 Van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-preserving orthotopic substitution entero-cystoplasty for interstitial cystitis. J Urol. 2002; 167: 603-607
  • 18 Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol. 1994; 152: 1641-1645
  • 19 Hurst RE, Rhodes SW, Adamson PB, Parsons CL, Roy JB. Functional and structural characteristics of the gly-cosaminoglycans of the bladder luminal surface. J Urol. 1987; 138: 433-437
  • 20 Parsons CL. A model for the function of glycosaminoglycans in the urinary tract. World J Urol. 1994; 12: 38-42
  • 21 Hurst RE, Roy JB, Parsons CL. The role of glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. In Sant GR. ed Interstitial Cystitis. Philadelphia (PA): Lippincott-Raven; 1997. p 93-100
  • 22 Hurst RE, Roy JB, Min KW, Veltri RW, Morley G, Patton K et al. A deficit of chondroitin sulphate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996; 48: 817-821
  • 23 Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004; 171: 1554-1558
  • 24 Steinhoff G, Ittah B, Rowan S. The efficacy of intravesicular sterile sodium chondroitin sulfate 0.2% in potassium tested positive patients with interstitial cystitis. Adv Exp Med Biol. 2003; 539: 731-739
  • 25 Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002; 9: 1454-1458
  • 26 Sorensen RB. Chondroitin sulfate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Uro Suppl. 2003; 2: 16-18
  • 27 Thuro-Schöffel HC. New therapeutic options for patients with chronic forms of cystitis. Urologe A. 2004; 43: Al-3
  • 28 Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997; 49 Suppl (5A) 111-113
  • 29 Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM et al. Results of treatment of refractory interstitial cys titis with intravesical hyaluronic acid. Urol Int. 1997; 59: 26-29
  • 30 Nordling J, Jorgensen S, Kallestrup E. Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study. Urology. 2001; 57 Suppl (6A) 123
  • 31 Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol. 2005; 39: 143-147
  • 32 Bade JJ, Laseur M, Nieuwenberg A, Van der Weele LT, Men-sink HJA. A placebo-controlled study of intravesical pento-sanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997; 79: 168-171
  • 33 Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994; 73: 504-507
  • 34 Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005; 14: 798-804
  • 35 Rawal N, Berggren L. Organization of acute pain services: a low-cost model. Pain. 1994; 57: 117-123
  • 36 Steinhoff G. The efficacy of chondroitin sulphate in treating interstitial cystitis. Eur Urol Suppl. 2003; 2: 14-16
  • 37 Gauruder-Burmester A, Wildt B, Tunn R. Treatment of overactive bladder with sodium chondroitin sulphate. J Zentralbl Gynäkol. 2006; 128: 336-340
  • 38 Strohmaier WL, Quack M, Wilbert DM, Bichler KH. Therapie der interstitiellen bzw. radiogenen Zystitis mit D-Glu-kosamin. Helv Chir Acta. 1989; 56: 323-325
  • 39 Parsons CL. Successful management of radiation cystitis with sodium pentosanpolysulfate. J Urol. 1986; 136: 813-814
  • 40 Hampson SJ, Woodhouse CRJ. Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: experience with 14 patients. Eur Urol. 1994; 25: 40-42
  • 41 Delgado Perez JM, Samper P, Garrido JS Hyaluronic acid in the prevention of radiation-induced cystitis, Abstract & poster book. Poster P22 presented at 55th annual meeting of the Northeastern Section of the American Urological Association. Halifax, Sept. 4–7 2003
  • 42 Staskin DR. Molecular activity and pharmacokinetics of anticholinergics for overactive bladder. Urology Times. 2004; Suppl. 6-8
  • 43 Dmochowski RR. New treatments for overactive bladder. Urology Times. 2004; Suppl. 10-2
  • 44 Manas A, Pena C, Sotoca A, Riviere M Prevention of urinary tract infections by the bladder instillation of hyaluronic acid (Cystistat) in patients suffering from medullary compression. Abstract. 55th annual meeting of the Northeastern Section of the American Urological Association. Halifax, Sept. 4–7, 2003